rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Medpace Holdings, Inc.

MEDP · Nasdaq

Health CareLife-science toolsIn trend

MEDP stood above a rising 150-day average in 25 of the last 52 weekly readings, including each of the last 6 weeks. It is 17.7% above that average now. Life Science Tools & Research Services: 52% of its 79 stocks in an uptrend (+1 points in four weeks); Health Care: 28% (−9 points in four weeks).

Statistics

Rotation
In trend
Weeks in an uptrend
6 in a row
Industry in uptrend
52% +1 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$667.0M
Officials’ trades on record
23
Institutions holding
651 (-31)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 25 of 52 weeks.

21 Apr – 20 Oct
27%44%61%Apr 26Jun 26Jul 26Sep 26Oct 26

Life-science tools: About half its stocks are in an uptrend and the share has held steady. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$213.4M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

23 disclosed lines: House 22, Senate 0, executive 1; 8 people.

WhoDidAmountTraded
David J. Taylor House: U.S. House ClerkOH02bought$1k–$15k15 May 2026filed 28 May 2026
David J. Taylor House: U.S. House ClerkOH02bought$1k–$15k15 May 2026filed 28 May 2026
David J. Taylor House: U.S. House ClerkOH02bought$1k–$15k26 Feb 2026filed 6 Mar 2026
Arjun Mody Executive branch: Office of Government EthicsSocial Security Administrationsold$1k–$15k30 Jan 2026filed 10 Apr 2026
David J. Taylor House: U.S. House ClerkOH02bought$1k–$15k29 Jan 2026filed 2 Feb 2026
David J. Taylor House: U.S. House ClerkOH02sold$1k–$15k16 Jan 2026filed 2 Feb 2026
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31sold$15k–$50k15 Jan 2026filed 13 Feb 2026
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31sold$1k–$15k9 Oct 2025filed 18 Nov 2025
Lisa C. McClain House: U.S. House ClerkMI09soldspouse$1k–$15k4 Aug 2025filed 12 Sep 2025
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31sold$1k–$15k24 Jul 2025filed 14 Aug 2025
David J. Taylor House: U.S. House ClerkOH02sold$1k–$15k23 Jul 2025filed 2 Sep 2025
Lisa C. McClain House: U.S. House ClerkMI09boughtspouse$1k–$15k22 Jul 2025filed 13 Aug 2025

Insiders

Buy orders, 12 months0
Sale orders, 12 months58
Buyers · sellers0 · 9
WhoDidSharesTraded
August J. TroendlePresident & CEOsold21,966at $625.4730 Sep 2026filed 1 Oct 2026
August J. TroendlePresident & CEOsold26,701at $621.0229 Sep 2026filed 1 Oct 2026
August J. TroendlePresident & CEOsold2,410at $620.0728 Sep 2026filed 29 Sep 2026
August J. TroendlePresident & CEOsold154at $620.6025 Sep 2026filed 29 Sep 2026
August J. TroendlePresident & CEOsold27,833at $621.3324 Sep 2026filed 25 Sep 2026
August J. TroendlePresident & CEOsold16,083at $628.6423 Sep 2026filed 25 Sep 2026
August J. TroendlePresident & CEOsold49,018at $628.1122 Sep 2026filed 23 Sep 2026
August J. TroendlePresident & CEOsold21,883at $623.2921 Sep 2026filed 23 Sep 2026
August J. TroendlePresident & CEOsold10,880at $620.4017 Sep 2026filed 21 Sep 2026
August J. TroendlePresident & CEOsold8,770at $621.2916 Sep 2026filed 17 Sep 2026
August J. TroendlePresident & CEOsold15,971at $620.8415 Sep 2026filed 17 Sep 2026
August J. TroendlePresident & CEOsold650at $620.2727 Aug 2026filed 31 Aug 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders651-31 on the quarter
New · exited73 · 107
Reported value$11.4B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 20262,498,248$1.3B+27,808+1.1%
AQR CAPITAL MANAGEMENT LLCreduced · filed 14 Aug 20261,278,935$677.3M-74,902−5.5%
VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 20261,133,357$600.2M+11,668+1.0%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20261,026,820$543.8M+15,749+1.6%
STATE STREET CORPadded · filed 7 Aug 2026710,895$376.5M+28,666+4.2%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026710,465$376.3M-34,641−4.6%
WASATCH ADVISORS LPreduced · filed 10 Jul 2026636,595$337.1M-137,336−17.7%
Invesco Ltd.added · filed 14 Aug 2026579,241$306.8M+1,667+0.3%
BAILLIE GIFFORD & COreduced · filed 6 Aug 2026473,211$250.6M-29,980−6.0%
ARROWSTREET CAPITAL, LIMITED PARTNERSHIPadded · filed 13 Aug 2026429,012$227.2M+33,243+8.4%
31 Mar 2023 – 30 Jun 2026
354538721Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Susan E. Burwig Company insiderExec. VP, Operations · last 12 Oct 20262 · 16
August J. Troendle Company insiderPresident & CEO · last 30 Sep 202619 · 243
Brian T. Carley Company insiderDirector · last 30 Sep 20260 · 2
Cornelius P. McCarthy III Company insiderDirector · last 30 Sep 20260 · 3
Robert O. Kraft Company insiderDirector · last 30 Sep 20260 · 6
Kevin M. Brady Company insiderCFO & Treasurer · last 20 Aug 20260 · 7
Fred B. Davenport Jr. Company insiderDirector · last 19 Aug 20261 · 3
Stephen P. Ewald Company insiderGeneral Counsel & Corp. Secy. · last 28 May 20261 · 15
Dani S. Zander Company insiderDirector · last 15 May 20260 · 0
David J. Taylor HouseOH02 · last 15 May 20264 · 2
Femida H. Gwadry-Sridhar Company insiderDirector · last 15 May 20260 · 0
Jesse J. Geiger Company insiderPresident · last 17 Mar 20260 · 22

Same industry

OABI OmniAbLeading+75%
TXG 10x GenomicsLeading+61%
AVTR AvantorLeading+48%
ILMN IlluminaLeading+46%
RVTY RevvityLeading+39%
MASS 908 DevicesLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Operating profit marginFY 2025 · to 31 Dec 202521.1%
Free cash flow marginFY 2025 · to 31 Dec 202526.9%
Return on capital employedFY 2025 · to 31 Dec 202584.7%
Cash conversionFY 2025 · to 31 Dec 2025158%
Share count trendFY 2025 · to 6 Feb 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$497.0M
Free cash flowFY 2025 · to 31 Dec 2025$681.9M

Analyst forecasts

No analyst forecasts yet.